BIOREGENX, INC. (BRGX)

SEC fundamentals · as filed in 10-Q FY2026, period ended Mar 31, 2026 · updated Oct 6, 2026

Verified against EDGAR
Total Assets
$337,070
Stockholders' Equity
-$4.5M
Cash & Equivalents
$45,806
Long-Term Debt
$1.2M

as filed in 10-Q FY2026, period ended Mar 31, 2026 · View filings on EDGAR ↗

In its 10-Q for the period ended Mar 31, 2026, BIOREGENX, INC. reported revenue of $426,175, net income of -$26,415, and total assets of $337,070. Every figure below is taken directly from BIOREGENX, INC.'s SEC filings: each links to the source document on EDGAR.

Revenue trend

Revenue · FY2021–FY2025 · as reported

$3.4M-$9.8M-$23.1M
FY2021FY2022FY2023FY2024FY2025
Revenue$1.9MNet income-$1.5M
FY2021 revenue
$198,584
FY2025 revenue
$1.9M

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2025$1.9M-$1.5M
FY2024$2.3M-$23.1M
FY2023$3.4M-$3.6M
FY2022$42,159-$78,308
FY2021$198,584-$96,873

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
10-QMay 20, 2026on EDGAR ↗
NT 10-QMay 15, 2026on EDGAR ↗
10-KApr 15, 2026on EDGAR ↗
NT 10-KApr 1, 2026on EDGAR ↗
10-QNov 14, 2025on EDGAR ↗
10-QAug 14, 2025on EDGAR ↗
10-QMay 15, 2025on EDGAR ↗
10-K/AApr 16, 2025on EDGAR ↗
10-KApr 15, 2025on EDGAR ↗
8-KApr 14, 2025on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Mar 31, 2026 · 10-Q

Total Assets$337,070source ↗
Stockholders’ Equity-$4.5Msource ↗
Cash & Equivalents$45,806source ↗
Long-Term Debt$1.2Msource ↗

Income Statement

10-Q (quarterly) · period ended Mar 31, 2026

Revenue$426,175source ↗
Net Income-$26,415source ↗
Operating Income-$49,764source ↗
Gross Profit$348,288source ↗
Cost of Revenue$77,887source ↗
R&D Expense—source ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Mar 31, 2026

EPS (diluted)$0.00source ↗
EPS (basic)$0.00source ↗
Shares Outstanding971.6Msource ↗
Cash from Operations$26,629source ↗
Cash from Financing-$50,206source ↗
Cash from Investing—source ↗

Restatement history

Point-in-time

18 of 143 annual fact-keys were materially restated between filings: what BIOREGENX, INC. first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.

See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.

Deeper fundamentals

A free API key reaches BRGX’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/BRGX

MCP tool: get_sec_fundamentals ticker=BRGX

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/BRGX/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=BRGX as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/BRGX/history

MCP tool: get_fundamentals_history ticker=BRGX

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/financial-health/BRGX

MCP tool: get_financial_health ticker=BRGX

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.